



1642

Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 09/932,678

Filing Date August 16, 2001

First Named Inventor Ronald H. Reeder

Group Art Unit 1642

Examiner Name Christopher H. Yaen

Total Number of Pages in This Submission

1

Attorney Docket Number

14538A-005810US

RECEIVED

JUL 08 2002

TECH CENTER 600/2900

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☒ Amendment / Response

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☐ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s)

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):

Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name Townsend and Townsend and Crew LLP
Brian W. Poor

Reg. No. 32,928

Signature

Brian W. Poor

Date

June 20, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

June 20, 2002

Typed or printed name Wendy Walton

Signature

Wendy Walton

Date

June 20, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 SE 5013040 v1

COPY OF PAPERS
ORIGINALLY FILED

COPY OF P~~ATENT~~
ORIGINALLY FILED

Section 1 #1
7.17.02


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents Washington, D.C. 20231 on

PATENT

Attorney Docket No.: 14538A-005810US

June 20, 2002

Wendy Webb



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Notification of:

Ronald H. Reeder *et al.*

Examiner: Christopher H. Yaen

Application No.: 09/932,678

Art Unit: 1642

Filed: August 16, 2001

For: HUMAN RRN3 AND
COMPOSITIONS AND METHODS
RELATING THERETO

RESPONSE TO RESTRICTION
REQUIREMENT

RECEIVED

JUL 08 2002

TECH CENTER 1600/29

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Restriction Requirement dated May 21 2002, which set forth the following groups of claims:

- I. Claims 1-5, 7-19, drawn to a purified nucleic acid, classified in class 536, subclass 23.1.
- II. Claims 6 and 27, drawn to an isolated polypeptide and functional fragments, classified in class 530, subclass 350.
- III. Claims 20-24, drawn to a method of producing a Rrn3 polypeptide, classified in class 435, subclass 70.1.
- IV. Claims 25 and 26, drawn to an antibody, classified in class 530, subclass 387.1.
- V. Claims 28-34, drawn to a method of identifying agonist and antagonist, classified in class 435, subclass 7.1.
- VI. Claims 35-38, drawn to a method of screening for hypoproliferative or hyperproliferative disease, classified in class 435, subclass 6.